Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Exelixis is conducting a Phase 2/3 clinical trial titled ‘A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors.’ The study aims to evaluate the effectiveness of zanzalintinib compared to everolimus in treating pancreatic and extra-pancreatic neuroendocrine tumors, which are challenging conditions with limited treatment options.
Intervention/Treatment: The trial tests two oral medications: zanzalintinib, an experimental drug, and everolimus, an active comparator. Both are administered as daily oral tablets, targeting previously treated, unresectable neuroendocrine tumors.
Study Design: This interventional study is randomized and follows a sequential intervention model with no masking. Its primary purpose is treatment, focusing on comparing the efficacy of the two drugs in a structured clinical setting.
Study Timeline: The study began on April 17, 2025, with the latest update submitted on August 25, 2025. These dates mark the progression and ongoing nature of the trial, which is currently in the recruiting phase.
Market Implications: The outcome of this study could significantly impact Exelixis’s market position, potentially boosting its stock performance if zanzalintinib proves effective. It may also influence investor sentiment positively, given the high demand for effective neuroendocrine tumor treatments. Competitors in the oncology sector will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.